Full Press Release Details
Inspira Technologies will Reveal the New ALICETM
Device at the World's Largest Extracorporeal Life Support Conference
The ELSO conference is a consortium of healthcare institutions, researchers,
and industry partners
Ra'anana, Israel, May 16, 2023 - Inspira Technologies
OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the "Company" or "Inspira Technologies"), a company aiming to
revolutionize acute respiratory care, has announced today it will reveal the new ALICETM device at the world's largest
Extracorporeal Life Support Organization (ELSO) conference, the 34th Annual ELSO Conference in Seattle, Washington, which will
be held between the 28th of September and the 1st of October 2023.
"Revealing the ALICE medical device to the medical community
at the ELSO conference in the U.S. marks an important milestone for the company and the first step towards Inspira's market penetration.
At the conference we plan to initiate commercial engagements," commented Joe Hayon, President of Inspira Technologies.
The ALICE is an extracorporeal blood circulation medical device allowing
for cardiac and pulmonary support. During the extracorporeal treatment, the ALICE device is designed to provide continuous enrichment
of the blood with oxygen and carbon dioxide removal. The device is designed with an innovative user interface and unique features aimed
to facilitate and enhance user experience. Prior to the ELSO conference, Inspira is planning to submit the ALICE medical device to the
U.S. Food and Drug Administration under the 510(k) pathway.
The Extracorporeal Life Support Organization (ELSO) is an international
nonprofit consortium of health care institutions, researchers, and industry partners. The organization provides support to those delivering
extracorporeal life support through continuing education, guidelines, original research, publications, and a comprehensive registry of
extracorporeal membrane oxygenation (ECMO) patient data. ECMO clinicians, research scientists, and members of regulatory and public health
institutions are eligible for membership in ELSO. There are currently over 20,000 users and center members from over 50 countries. Memberships
allows physicians, nurses, perfusionists, respiratory therapists, researchers and other healthcare professionals to become more directly
involved in the world's largest ECMO community.
About Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company in
the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to
rebalance patient oxygen saturation levels. This technology potentially allows patients to remain awake during treatment while reducing
the need for highly invasive, risky, and costly mechanical ventilation systems that require intubation and medically induced coma. The
Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.
For more information, please visit our corporate website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements
pursuant to U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations
of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it
discusses that it intends to initiate commercial engagements at the conference and that it intends to make an FDA submission of the ALICE
device via a 510(k) pathway prior to the ELSO conference. These forward-looking statements and their implications are based solely on
the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company
undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting
the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal
year ended December 31, 2022 filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the
SEC's website, www.sec.gov
US Public Relations and Investor Relations
RedChip Companies Inc.
1-800-RED-CHIP (733-2447)